Multifactorial Prognostication of the Development of Stent Thrombosis in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention on the background of Dual Antiplatelet Therapy

Aim: to identify predictors of stent thrombosis in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI) for 12 months by creating a miathematical logistic regression model to optimize rehabilitation, secondary prevention of ischemic events in the first year after ACS, as well as a personalized approach to treatment. Materials and methods. The analysis used data from the hospital register, which contained information on all PCIs, performed in the Semashko hospital between September 2016 and August 2018 (2378 patients). For this study we selected a sample of 183 ACS patients (146 men and 37 women) after PCI: 25 with definite stent thrombosis confirmed by repeated coronary angiography (CAG) (the main study group), and 158 without developing definite stent thrombosis (the comparison group) according to the observation for 12 months. All patients during hospitalization and 1 year after discharge received standard medical therapy ACS, according to international recommendations. Laboratory tests, electrocardiography (ECG), echocardiography, 24-hour ECG monitoring were performed for in patients. For determining predictors of the development of stent thrombosis we performed a logistic regression analysis. Results. A mathematical model of multifactorial prognostication of stent thrombosis in patients with ACS after PCI was created. The model included the following predictors: Killip class >II; life-threatening paroxysmal tachyarrhythmias (atrial fibrillation and/or ventricular fibrillation) as ACS complication of; left ventricular ejection fraction ≤45%; CA dissection; CAG confirmed CA thrombosis before PCI. Conclusion. The proposed model in patients with ACS allows us to estimate the risk of stent thrombosis after PCI, as well as to improve the accuracy of the event prediction. The model is easy to use, can be applied by practicing cardiologists during hospitalization. This model allows us to personalize secondary prevention in the first year after ACS, and thus help to reduce cardiovascular mortality, incidence of recurrent myocardial infarctions, unstable angina, and emergency revascularization.

1. Jaffe R., Strauss B.H. Late and very late thrombosis of drug eluting stents: evolving concepts and perspectives. J. Amer. Coll. Cardiol., 2007, 50,119-127. DOI: 10.1016/j.jacc.2007.04.031

2. Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium . Eur Heart J (2016) 37 (19): 1538-1549. DOI: 10.1093/eurheartj/ehv419

3. Urban P., Gershlick А.Н., Guagliumi G. et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006; 113:11:1434-41.

4. Roy P., Torguson R., Okabe T. et al. Comparison between sirolimus - and paclitaxel-eluting stents in complex patient and lesions subsets. Catheter Cardiovasc. Interv. 2007; 70: 2: 167-72

5. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006;355:1093–10

6. Cutlip D.E., Windecker S., Mehran R. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351. DOI:10.1161/CIRCULATIONAHA.106.685313.

7. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) 2017 Eur Heart J. 2017 Aug;26 DOI:10.1093/eurheartj/ehx393

8. Sianos G, Papafaklis MI, Serruys PW. Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. J Invasive Cardiol. 2010; 22:6B–14B.

9. Gibson CM, de Lemos JA, Murphy SA et al. Combination therapy with abciximab reduces angiographically evident thrombus in acutemyocardial infarction: a TIMI 14 substudy. Circulation. 2001 May 29; 103(21):2550-4.